07/30/2021 | Press release | Distributed by Public on 07/30/2021 16:54
Submission of Matters to a Vote of Security Holders.
On July 30, 2021, Onconova Therapeutics, Inc. (the 'Company') held its 2021 Annual Meeting of Stockholders (the 'Annual Meeting'). As previously disclosed in Form 8-Ks filed on June 25, 2021 and July 16, 2021, the Company had adjourned its Annual Meeting due to a lack of quorum. A total of 7,965,991 shares were represented at the Annual Meeting, which represented a quorum. At the Annual Meeting, the stockholders of the Company voted on the below proposals. The voting results on these proposals were as follows:
Proposal 1. To elect six directors, each to hold office until the 2022 Annual Meeting of Stockholders and until his or her successor is elected and qualified. Each nominee for director was elected by a vote of the stockholders as follows:
|Steven M. Fruchtman, M.D.||3,581,253||904,519||3,480,219|
|Jerome E. Groopman, M.D.||3,488,719||997,053||3,480,219|
|James J. Marino||3,599,873||885,899||3,480,219|
|M. Teresa Shoemaker||3,623,576||862,196||3,480,219|
|Jack E. Stover||3,611,580||874,192||3,480,219|
Proposal 2 To consider and vote upon the 2021 Incentive Compensation Plan. The proposal was approved by a vote of the stockholders as follows:
Proposal 3. To approve, on an advisory basis, the compensation of our named executive officers. The proposal was approved by a vote of the
stockholders as follows:
Proposal 4. To consider and vote upon the ratification of the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021. The proposal was approved by a vote of the stockholders as follows:
With regard to Proposal 3, the Company's Compensation Committee of the Board of Directors takes note of the results of the advisory 'say-on-pay' proposal and expects to consider these results and feedback received from the Company's ongoing stockholder engagement program, among the factors considered in connection with continuing to discharge its responsibilities in setting the compensation of the Company's named executive officers.